Sign in
4

Changes in Ownership

HALOZYME THERAPEUTICS, INC. Filed Acc 0001415889-25-021681

PRESIDENT AND CEO sold 60,000 shares at an average $63.62 ($3,817,389)

  • PRESIDENT AND CEO acquired 60,000 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Torley Helen · PRESIDENT AND CEO

Table I: Non-derivative

9 lines
Date Transaction Shares Price Value Owned after D/I
2025-08-11 Exercise or conversion : show line 1 in the form 10b5-1 +20,000 $8.11 $162,200 753,719 D
2025-08-11 Sale : show line 2 in the form 10b5-1 −18,717 $63.01 $1,179,321 735,002 D
2025-08-11 Sale : show line 3 in the form 10b5-1 −1,283 $63.60 $81,596 733,719 D
2025-08-12 Exercise or conversion : show line 4 in the form 10b5-1 +20,000 $8.11 $162,200 753,719 D
2025-08-12 Sale : show line 5 in the form 10b5-1 −13,042 $63.24 $824,802 740,677 D
2025-08-12 Sale : show line 6 in the form 10b5-1 −6,958 $64.00 $445,319 733,719 D
2025-08-13 Exercise or conversion : show line 7 in the form 10b5-1 +20,000 $8.11 $162,200 753,719 D
2025-08-13 Sale : show line 8 in the form 10b5-1 −14,948 $64.15 $958,839 738,771 D
2025-08-13 Sale : show line 9 in the form 10b5-1 −5,052 $64.83 $327,511 733,719 D
Open-market sales · 60,000 sh · avg $63.62 · $3,817,389

Table II: Derivative

3 lines
Date Transaction Shares Price Value Owned after D/I
2025-08-11 Exercise or conversion : show line 10 in the form 10b5-1 Option to Purchase Common Stock −20,000 $8.11 $162,200 236,569 D
2025-08-12 Exercise or conversion : show line 11 in the form 10b5-1 Option to Purchase Common Stock −20,000 $8.11 $162,200 216,569 D
2025-08-13 Exercise or conversion : show line 12 in the form 10b5-1 Option to Purchase Common Stock −20,000 $8.11 $162,200 196,569 D
Loading xslF345X05/form4-08132025_100858.xml…